PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology.

Pathological accumulation of intermediate filaments can be observed in neurodegenerative disorders, such as Alzheimer's disease, frontotemporal dementia and Parkinson's disease, and is also characteristic of neuronal intermediate filament inclusion disease. Intermediate filaments type IV include three neurofilament proteins (light, medium and heavy molecular weight neurofilament subunits) and α-internexin. The phosphorylation of intermediate filament proteins contributes to axonal growth, and is regulated by protein kinase A. Here we describe a family with a novel late-onset neurodegenerative disorder presenting with dementia and/or parkinsonism in 12 affected individuals. The disorder is characterized by a unique neuropathological phenotype displaying abundant neuronal inclusions by haematoxylin and eosin staining throughout the brain with immunoreactivity for intermediate filaments. Combining linkage analysis, exome sequencing and proteomics analysis, we identified a heterozygous c.149T>G (p.Leu50Arg) missense mutation in the gene encoding the protein kinase A type I-beta regulatory subunit (PRKAR1B). The pathogenicity of the mutation is supported by segregation in the family, absence in variant databases, and the specific accumulation of PRKAR1B in the inclusions in our cases associated with a specific biochemical pattern of PRKAR1B. Screening of PRKAR1B in 138 patients with Parkinson's disease and 56 patients with frontotemporal dementia did not identify additional novel pathogenic mutations. Our findings link a pathogenic PRKAR1B mutation to a novel hereditary neurodegenerative disorder and suggest an altered protein kinase A function through a reduced binding of the regulatory subunit to the A-kinase anchoring protein and the catalytic subunit of protein kinase A, which might result in subcellular dislocalization of the catalytic subunit and hyperphosphorylation of intermediate filaments.

[1]  V. Timmerman,et al.  Neurofilament phosphorylation and their proline‐directed kinases in health and disease , 2012, Journal of the peripheral nervous system : JPNS.

[2]  Mason R. Mackey,et al.  A Small Novel A-Kinase Anchoring Protein (AKAP) That Localizes Specifically Protein Kinase A-Regulatory Subunit I (PKA-RI) to the Plasma Membrane* , 2012, The Journal of Biological Chemistry.

[3]  R. Nixon,et al.  The C-Terminal Domains of NF-H and NF-M Subunits Maintain Axonal Neurofilament Content by Blocking Turnover of the Stationary Neurofilament Network , 2012, PloS one.

[4]  Ping Zhang,et al.  Assembly of allosteric macromolecular switches: lessons from PKA , 2012, Nature Reviews Molecular Cell Biology.

[5]  Susan S. Taylor,et al.  Localization and quaternary structure of the PKA RIβ holoenzyme , 2012, Proceedings of the National Academy of Sciences.

[6]  A. Rogers,et al.  Molecular Pathways: The Role of NR4A Orphan Nuclear Receptors in Cancer , 2012, Clinical Cancer Research.

[7]  J. M. Dale,et al.  Neurofilament Phosphorylation during Development and Disease: Which Came First, the Phosphorylation or the Accumulation? , 2012, Journal of amino acids.

[8]  N. Cairns,et al.  Gigaxonin mutation analysis in patients with NIFID , 2011, Neurobiology of Aging.

[9]  L. Annunziato,et al.  Control of PKA stability and signalling by the RING ligase praja2 , 2011, Nature Cell Biology.

[10]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[11]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[12]  Susan S. Taylor,et al.  Structure of D-AKAP2:PKA RI complex: insights into AKAP specificity and selectivity. , 2010, Structure.

[13]  M. Strong,et al.  Post-transcriptional control of neurofilaments: New roles in development, regeneration and neurodegenerative disease , 2010, Trends in Neurosciences.

[14]  H. Kretzschmar,et al.  Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease , 2009, Acta Neuropathologica.

[15]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[16]  I. Bossis,et al.  In vitro functional studies of naturally occurring pathogenic PRKAR1A mutations that are not subject to nonsense mRNA decay , 2008, Human mutation.

[17]  Maria Martinez-Lage,et al.  Clinical and pathological heterogeneity of neuronal intermediate filament inclusion disease. , 2008, Archives of neurology.

[18]  J. Morris,et al.  TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. , 2007, The American journal of pathology.

[19]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[20]  J. Hardy,et al.  Mutation analysis of patients with neuronal intermediate filament inclusion disease (NIFID) , 2006, Neurobiology of Aging.

[21]  T. Gotow,et al.  Aggregate formation and phosphorylation of neurofilament-L Pro22 Charcot-Marie-Tooth disease mutants. , 2006, Human molecular genetics.

[22]  Tom H. Lindner,et al.  easyLINKAGE-Plus--automated linkage analyses using large-scale SNP data , 2005, Bioinform..

[23]  D. Dickson,et al.  Screening for neurofilament inclusion disease using α-internexin immunohistochemistry , 2005, Neurology.

[24]  J. Trojanowski,et al.  Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease , 2004, Neurology.

[25]  J. Trojanowski,et al.  alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. , 2004, The American journal of pathology.

[26]  J. Trojanowski,et al.  α-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases , 2004, Acta Neuropathologica.

[27]  C. Angiari,et al.  Giant axon and neurofilament accumulation in Charcot–Marie–Tooth disease type 2E , 2004, Neurology.

[28]  D. Wotton Faculty Opinions recommendation of A transforming growth factor beta-induced Smad3/Smad4 complex directly activates protein kinase A. , 2004 .

[29]  Robert C. Edgar,et al.  MUSCLE: multiple sequence alignment with high accuracy and high throughput. , 2004, Nucleic acids research.

[30]  M. Uhler,et al.  A Transforming Growth Factor β-Induced Smad3/Smad4 Complex Directly Activates Protein Kinase A , 2004, Molecular and Cellular Biology.

[31]  Nick C Fox,et al.  Neurofilament inclusion body disease: a new proteinopathy? , 2003, Brain : a journal of neurology.

[32]  Veeranna,et al.  Phosphorylation of the Head Domain of Neurofilament Protein (NF-M) , 2003, Journal of Biological Chemistry.

[33]  J. Warsh,et al.  Altered cAMP‐dependent protein kinase subunit immunolabeling in post‐mortem brain from patients with bipolar affective disorder , 2003, Journal of neurochemistry.

[34]  K. Taskén,et al.  Specificity in the cAMP/PKA signaling pathway. differential expression, regulation, and subcellular localization of subunits of PKA. , 2000, Frontiers in bioscience : a journal and virtual library.

[35]  Daniel F. Gudbjartsson,et al.  Allegro, a new computer program for multipoint linkage analysis , 2000, Nature genetics.

[36]  R. Roos,et al.  Numerous and widespread α-synuclein-negative Lewy bodies in an asymptomatic patient , 1999, Acta Neuropathologica.

[37]  R. Liem,et al.  Overexpression of α-Internexin Causes Abnormal Neurofilamentous Accumulations and Motor Coordination Deficits in Transgenic Mice , 1999, The Journal of Neuroscience.

[38]  R. Nixon,et al.  Serine‐23 Is a Major Protein Kinase A Phosphorylation Site on the Amino‐Terminal Head Domain of the Middle Molecular Mass Subunit of Neurofilament Proteins , 1999, Journal of neurochemistry.

[39]  J R O'Connell,et al.  PedCheck: a program for identification of genotype incompatibilities in linkage analysis. , 1998, American journal of human genetics.

[40]  M. Stryker,et al.  Comparison of Plasticity In Vivo and In Vitro in the Developing Visual Cortex of Normal and Protein Kinase A RIβ-Deficient Mice , 1998, The Journal of Neuroscience.

[41]  C. Miller,et al.  Neuropathological Abnormalities in Transgenic Mice Harbouring a Phosphorylation Mutant Neurofilament Transgene , 1998, Journal of neurochemistry.

[42]  J. Scott,et al.  Type II regulatory subunits are not required for the anchoring-dependent modulation of Ca2+ channel activity by cAMP-dependent protein kinase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  E R Kandel,et al.  Impaired hippocampal plasticity in mice lacking the Cbeta1 catalytic subunit of cAMP-dependent protein kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E R Kandel,et al.  Hippocampal long-term depression and depotentiation are defective in mice carrying a targeted disruption of the gene encoding the RI beta subunit of cAMP-dependent protein kinase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[46]  Jean-Pierre Julien,et al.  Functions of intermediate filaments in neuronal development and disease. , 2004, Journal of neurobiology.

[47]  R. Roos,et al.  Numerous and widespread alpha-synuclein-negative Lewy bodies in an asymptomatic patient. , 1999, Acta neuropathologica.